行情

CNCE

CNCE

Concert Pharma
NASDAQ

实时行情|Nasdaq Last Sale

8.15
-0.26
-3.09%
盘后: 8.15 0 0.00% 16:00 04/07 EDT
开盘
8.61
昨收
8.41
最高
8.61
最低
8.00
成交量
13.63万
成交额
--
52周最高
13.19
52周最低
5.36
市值
2.42亿
市盈率(TTM)
-2.4742
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CNCE价格均价为21.63,最高价位30.00,最低价为11.00。

EPS

CNCE 新闻

更多
  • Twitter创始人宣布捐献10亿美元抗击新冠病毒
  • 新浪科技 · 1小时前
  • 特朗普:美国将研究暂扣为世卫组织提供的资金
  • 新浪美股 · 1小时前
  • 隔夜要闻:道指回吐逾900点涨幅 美油下挫逾9%
  • 新浪美股 · 1小时前
  • 桥水达利欧:当印刷机不断印钞 仍认为现金就是垃圾
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
-2.89%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

CNCE 简况

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
展开

微牛提供Concert Pharmaceuticals Inc(NASDAQ-CNCE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CNCE股票新闻,以帮助您做出投资决策。